文献速递免疫规划

Advax-CpG佐剂重组H5血凝素疫苗保护小鼠抵抗致死性流感感染

An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
PubMed 文献 · Vaccine · 2023-08-09

本研究测试了Delta菊粉佐剂(Advax™)单独或联合TLR9激动剂(Advax-CpG™)增强昆虫细胞表达的重组H5血凝素抗原(rH5HA)免疫原性及保护小鼠抵抗致死性流感感染的能力。Advax佐剂rH5HA诱导高血清血凝抑制活性及Th1/Th2细胞因子分泌性CD4和CD8 T细胞,免疫保护小鼠抵抗致死性异亚型H5N1病毒攻击。Advax佐剂rHA2茎部抗原诱导的血清抗体无血凝抑制活性,但可转移保护抵抗致死性H1N1或H3N2感染至naïve小鼠。

要点

  • Advax佐剂rH5HA诱导高血凝抑制活性及Th1/Th2细胞因子分泌性CD4和CD8 T细胞。
  • 免疫保护小鼠抵抗致死性异亚型H5N1病毒攻击。
  • Advax佐剂rHA2茎部抗原诱导的抗HA2抗体无血凝抑制活性但可转移保护抵抗致死性H1N1或H3N2感染。

核心结论

  • Advax佐剂rH5HA诱导的保护可能由针对HA头部的中和抗体、抗HA2茎部抗体及记忆CD4+和CD8+ T细胞共同介导。
  • 结果支持进一步开发Advax佐剂rH5大流行流感疫苗平台。

研究设计与样本

  • 研究测试Advax™单独或联合TLR9激动剂(Advax-CpG™)增强昆虫细胞表达的重组H5血凝素抗原(rH5HA)免疫原性及保护小鼠抵抗致死性流感感染的能力。

主要发现

  • Advax佐剂rH5HA诱导高血清血凝抑制活性及Th1和Th2细胞因子分泌性CD4和CD8 T细胞。
  • 免疫保护小鼠抵抗致死性异亚型H5N1病毒攻击。
  • Advax佐剂rHA2茎部抗原(经酶切rH5HA制备)诱导的血清抗体无血凝抑制活性,但可转移保护抵抗致死性H1N1或H3N2感染至naïve小鼠。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a major unmet need for strategies to improve the immunogenicity of vaccines to protect against highly pathogenic avian influenza strains with pandemic potential. This study tested the ability of adjuvants based on delta inulin (Advax™) alone or combined with a TLR9 agonist (Advax-CpG™) to enhance the immunogenicity of recombinant H5 hemagglutinin antigen expressed in insect cells (rH5HA) to protect mice against lethal influenza infection. The Advax-adjuvanted rH5HA induced high serum hemagglutination inhibition activity, as well as Th1 and Th2 cytokine secreting CD4 and CD8 T cells. Immunization protected mice against a lethal heterosubtypic H5N1 virus challenge. Mice immunized with an Advax-adjuvanted rHA2 stem antigen prepared by enzymatic cleavage of rH5HA produced serum antibodies devoid of hemagglutination inhibition activity, but these anti-HA2 antibodies were nevertheless able to transfer protection against lethal H1N1 or H3N2 infections to naïve mice. We hypothesize that the enhanced protection afforded by Advax-adjuvanted rH5HA may be mediated by the combination of neutralizing antibodies directed at the HA head, anti-HA2 stem antibodies plus memory CD4 + and CD8 + T cells. This outcome supports further development of the Advax-adjuvanted rH5 pandemic influenza vaccine platform.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Honda-Okubo Y, Bart Tarbet E, Hurst BL, et al. An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection. Vaccine. 2023. PMID: 37567799. doi:10.1016/j.vaccine.2023.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。